Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.19 -0.4%	$1.22	$0.86 ▼ $3.78	$262.93M	0.35	4.40 million shs	4.19 million shs
CRMD CorMedix	$13.73 +0.3%	$12.28	$5.31 ▼ $17.43	$1.02B	1.71	1.94 million shs	1.68 million shs
MLYS Mineralys Therapeutics	$14.69 -1.4%	$14.00	$8.24 ▼ $18.38	$973.54M	-0.29	881,893 shs	674,425 shs
NUVB Nuvation Bio	$2.87 -1.2%	$2.27	$1.54 ▼ $3.45	$980.60M	1.35	4.26 million shs	2.96 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	+8.18%	-20.67%	+12.26%	-54.41%
CRMD CorMedix	0.00%	+5.88%	+19.15%	+10.76%	+142.30%
MLYS Mineralys Therapeutics	0.00%	+2.55%	+3.98%	-6.70%	+28.25%
NUVB Nuvation Bio	0.00%	+5.16%	+15.91%	+25.19%	+0.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	2.6355 of 5 stars	3.4	3.0	1.6	2.5	0.6
CRMD CorMedix	2.6282 of 5 stars	3.4	1.0	3.3	0.0	1.9
MLYS Mineralys Therapeutics	3.2713 of 5 stars	3.4	3.0	3.5	4.2	0.0
NUVB Nuvation Bio	2.3227 of 5 stars	3.6	1.0	2.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.75	Moderate Buy	$8.44	612.61% Upside
CRMD CorMedix	2.88	Moderate Buy	$16.71	21.74% Upside
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	119.61% Upside
NUVB Nuvation Bio	3.17	Buy	$7.33	155.96% Upside

Current Analyst Ratings Breakdown

Latest ALLO, CRMD, MLYS, and NUVB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
8/8/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $17.00
8/8/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00
8/4/2025	ALLO Allogene Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/4/2025	ALLO Allogene Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
6/30/2025	CRMD CorMedix	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/30/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/30/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
6/25/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/24/2025	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $20.00
6/23/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	13,146.39	N/A	N/A	$2.01 per share	0.59
CRMD CorMedix	$43.47M	23.58	N/A	N/A	$1.40 per share	9.81
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
NUVB Nuvation Bio	$7.87M	124.60	N/A	N/A	$1.37 per share	2.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.11	N/A	N/A	N/A	N/A	-55.99%	-42.75%	11/6/2025 (Estimated)
CRMD CorMedix	-$17.93M	$0.75	18.29	14.61	N/A	42.11%	42.73%	34.19%	10/29/2025 (Estimated)
MLYS Mineralys Therapeutics	-$177.81M	-$3.56	N/A	N/A	N/A	N/A	-70.44%	-65.51%	11/10/2025 (Estimated)
NUVB Nuvation Bio	-$567.94M	-$0.63	N/A	N/A	N/A	-1,413.43%	-46.14%	-36.04%	11/5/2025 (Estimated)

Latest ALLO, CRMD, MLYS, and NUVB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ALLO Allogene Therapeutics	-$0.28	-$0.23	+$0.05	-$0.23	N/A	N/A
8/12/2025	Q2 2025	MLYS Mineralys Therapeutics	-$0.78	-$0.66	+$0.12	-$0.66	N/A	N/A
8/7/2025	Q2 2025	CRMD CorMedix	$0.20	$0.28	+$0.08	$0.28	$29.88 million	$39.74 million
8/7/2025	Q2 2025	NUVB Nuvation Bio	-$0.17	-$0.17	N/A	-$0.17	$0.42 million	$4.83 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	8.92	8.92
CRMD CorMedix	N/A	7.82	7.52
MLYS Mineralys Therapeutics	N/A	15.12	15.12
NUVB Nuvation Bio	0.13	9.39	9.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
CRMD CorMedix	34.18%
MLYS Mineralys Therapeutics	84.46%
NUVB Nuvation Bio	61.67%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
CRMD CorMedix	5.30%
MLYS Mineralys Therapeutics	25.56%
NUVB Nuvation Bio	29.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	221.88 million	192.59 million	Optionable
CRMD CorMedix	30	74.65 million	70.69 million	Optionable
MLYS Mineralys Therapeutics	28	66.30 million	44.26 million	Optionable
NUVB Nuvation Bio	60	342.27 million	239.83 million	Optionable

ALLO, CRMD, MLYS, and NUVB Headlines

Recent News About These Companies

Nuvation Bio Inc. $NUVB Shares Acquired by Algert Global LLC

August 24 at 4:50 AM | marketbeat.com

Wall Street Zen Upgrades Nuvation Bio (NYSE:NUVB) to Hold

August 18, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Trading 9.7% Higher - Still a Buy?

August 15, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Announces Quarterly Earnings Results

August 11, 2025 | marketbeat.com

Royal Bank Of Canada Increases Nuvation Bio (NYSE:NUVB) Price Target to $7.00

August 10, 2025 | marketbeat.com

Wedbush Reaffirms Their Buy Rating on Nuvation Bio (NUVB)

August 10, 2025 | theglobeandmail.com

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

August 10, 2025 | theglobeandmail.com

Wall Street Zen Downgrades Nuvation Bio (NYSE:NUVB) to Sell

August 10, 2025 | marketbeat.com

H.C. Wainwright Sticks to Their Buy Rating for Nuvation Bio (NUVB)

August 9, 2025 | theglobeandmail.com

NUVB Sales Jump 1,043% on Drug Launch

August 7, 2025 | aol.comA

Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates

August 7, 2025 | zacks.com

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025 | gurufocus.com

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025 | businesswire.com

Nuvation Bio Inc. (NYSE:NUVB) Given Average Rating of "Buy" by Brokerages

August 2, 2025 | marketbeat.com

Nuvation Bio (NUVB)’s Taletrectinib Selected as Preferred Agent for Cancer Treatment

August 1, 2025 | finance.yahoo.com

GSA Capital Partners LLP Has $1.16 Million Stock Position in Nuvation Bio Inc. (NYSE:NUVB)

August 1, 2025 | marketbeat.com

RBC Capital Maintains a Buy on Nuvation Bio (NUVB) With a $6 PT

August 1, 2025 | msn.com

Institutional investors may adopt severe steps after Nuvation Bio Inc.'s (NYSE:NUVB) latest 5.9% drop adds to a year losses

July 31, 2025 | finance.yahoo.com

Nuvation Bio (NUVB) Expected to Announce Earnings on Thursday

July 31, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Trading 8.6% Higher - Should You Buy?

July 29, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Upgraded at Wall Street Zen

July 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALLO, CRMD, MLYS, and NUVB Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.18 -0.01 (-0.42%)

As of 03:47 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

CorMedix NASDAQ:CRMD

$13.73 +0.04 (+0.29%)

As of 03:48 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Mineralys Therapeutics NASDAQ:MLYS

$14.68 -0.21 (-1.38%)

As of 03:47 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Nuvation Bio NYSE:NUVB

$2.86 -0.04 (-1.21%)

As of 03:47 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time